Protalix BioTherapeutics (PLX) Competitors $1.45 -0.01 (-0.68%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.46 +0.02 (+1.03%) As of 08/1/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLX vs. KOD, PGEN, PRTC, RGNX, SVRA, KMDA, CMPX, PVLA, FULC, and GOSSShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Kodiak Sciences (KOD), Precigen (PGEN), PureTech Health (PRTC), REGENXBIO (RGNX), Savara (SVRA), Kamada (KMDA), Compass Therapeutics (CMPX), Palvella Therapeutics (PVLA), Fulcrum Therapeutics (FULC), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Its Competitors Kodiak Sciences Precigen PureTech Health REGENXBIO Savara Kamada Compass Therapeutics Palvella Therapeutics Fulcrum Therapeutics Gossamer Bio Protalix BioTherapeutics (NYSE:PLX) and Kodiak Sciences (NASDAQ:KOD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk. Does the media refer more to PLX or KOD? In the previous week, Protalix BioTherapeutics had 1 more articles in the media than Kodiak Sciences. MarketBeat recorded 1 mentions for Protalix BioTherapeutics and 0 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.00 beat Protalix BioTherapeutics' score of -0.91 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Overall Sentiment Protalix BioTherapeutics Negative Kodiak Sciences Neutral Do insiders and institutionals believe in PLX or KOD? 16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 45.9% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is PLX or KOD more profitable? Kodiak Sciences has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Kodiak Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% Kodiak Sciences N/A -115.71%-54.17% Which has higher valuation & earnings, PLX or KOD? Protalix BioTherapeutics has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$59.76M1.93$8.31M$0.0436.25Kodiak SciencesN/AN/A-$176.21M-$3.63-1.83 Do analysts rate PLX or KOD? Protalix BioTherapeutics currently has a consensus target price of $15.00, indicating a potential upside of 934.48%. Kodiak Sciences has a consensus target price of $9.00, indicating a potential upside of 35.34%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Protalix BioTherapeutics is more favorable than Kodiak Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, PLX or KOD? Protalix BioTherapeutics has a beta of -0.23, indicating that its stock price is 123% less volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500. SummaryProtalix BioTherapeutics beats Kodiak Sciences on 8 of the 14 factors compared between the two stocks. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$115.43M$267.92M$5.49B$20.65BDividend YieldN/AN/A4.73%3.67%P/E Ratio-11.15N/A28.7829.03Price / Sales1.93327.48372.2066.13Price / Cash17.8022.4435.4522.84Price / Book3.0910.418.274.43Net Income$8.31M-$106.40M$3.25B$994.22M7 Day Performance-3.97%-7.85%-3.70%-3.39%1 Month Performance-3.33%18.32%4.34%-2.09%1 Year Performance38.10%6.03%25.90%10.09% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeutics2.2289 of 5 stars$1.45-0.7%$15.00+934.5%+36.2%$115.43M$59.76M-11.15200News CoverageGap UpKODKodiak Sciences3.3316 of 5 stars$8.24-6.8%$9.00+9.2%+130.1%$466.43MN/A0.0090Gap DownPGENPrecigen3.9979 of 5 stars$1.58+0.6%$6.00+279.7%+16.8%$463.43M$3.92M0.00190News CoveragePositive NewsOptions VolumePRTCPureTech Health1.4348 of 5 stars$19.09+0.1%$45.00+135.8%-12.1%$458.15M$4.83M0.00100Gap DownRGNXREGENXBIO4.114 of 5 stars$8.79-1.9%$31.63+259.8%-38.5%$449.44M$83.33M0.00370News CoverageUpcoming EarningsGap DownSVRASavara1.4861 of 5 stars$2.66+3.1%$5.60+110.5%-43.0%$445.92MN/A0.0020High Trading VolumeKMDAKamada4.4702 of 5 stars$7.68-0.5%$13.00+69.3%+30.3%$443.94M$160.95M26.62360News CoverageGap UpCMPXCompass Therapeutics2.3795 of 5 stars$3.20+0.6%$12.67+295.8%+196.2%$439.74M$850K-7.8020Positive NewsPVLAPalvella Therapeutics2.6822 of 5 stars$39.87+3.2%$47.50+19.1%N/A$426.97M$42.81M0.00N/AFULCFulcrum Therapeutics2.2606 of 5 stars$7.81flat$6.29-19.5%-24.2%$421.58M$80M0.00100Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionGOSSGossamer Bio3.9158 of 5 stars$1.98+7.6%$8.25+316.7%+127.3%$418.24M$114.70M0.00180News CoveragePositive NewsOptions Volume Related Companies and Tools Related Companies Kodiak Sciences Alternatives Precigen Alternatives PureTech Health Alternatives REGENXBIO Alternatives Savara Alternatives Kamada Alternatives Compass Therapeutics Alternatives Palvella Therapeutics Alternatives Fulcrum Therapeutics Alternatives Gossamer Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PLX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLX Stock Alerts